Arctic Bioscience AS ( (DE:9TD) ) just unveiled an update.
Arctic Bioscience has completed the HeROPA phase 2b clinical study for its drug candidate HRO350, intended for patients with mild-to-moderate psoriasis. Although the topline data was initially expected by the end of Q1 2025, the extensive dataset from over 500 patients requires more time for cleaning and quality control. The results are now anticipated within 2-3 weeks, with a full clinical study report to follow in May, potentially impacting the company’s market positioning and stakeholder interests.
More about Arctic Bioscience AS
Arctic Bioscience is a biotechnology company that develops and commercializes pharmaceutical products and dietary supplements derived from unique bioactive marine raw materials. The company is focused on developing HRO350, an oral drug candidate for treating mild-to-moderate psoriasis, and sells dietary supplements globally under the brand name ROMEGA®.
YTD Price Performance: 276.92%
Average Trading Volume: 1,875
Technical Sentiment Signal: Hold
Current Market Cap: €13.97M
See more insights into 9TD stock on TipRanks’ Stock Analysis page.